Novartis pill gets U.S. breakthrough designation in breast cancer

ZURICH, Aug 3 (Reuters) - Novartis AG breast cancer

pill LEE011 has won breakthrough therapy designation from U.S.

regulators as a first-line treatment for a form of advanced

breast cancer, the Swiss...

Read more